Mangoceuticals Inc (MGRX)

Mangoceuticals, Inc. is a U.S.-based company focused on men’s wellness through a telemedicine platform. It develops, markets, and sells products and services tied to areas such as erectile dysfunction, hair loss, hormone balance and therapy, weight management, and testosterone replacement. The company’s portfolio includes products sold under the Mango, Grow, Mojo, Slim, and Prime brands, and it also provides customers with access to a licensed pharmacy for online fulfillment of medications that may be prescribed during telehealth consultations. Mangoceuticals sells its products through its website, MangoRX.com. Incorporated in 2021, the company is headquartered in Dallas, Texas, and is a subsidiary of Cohen Enterprises, Inc.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-MGRX
$0.44
-7.4% Downside
Fair
Not available
Not available
Fair
0.0%
November 13, 2026
0.8x
32.6x
10.266 M
10.315 M
2.8%
82.7%
-201.7
23.9%
Valuation • Fair Value

Mangoceuticals Inc (NASDAQ-MGRX) Fair Value by Valuation Model

Review the available estimates for Mangoceuticals Inc (NASDAQ-MGRX), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.44

Estimated downside of 7.4% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.41

Discounted cash flow valuation reference.

EPV Fair Value

$0.50

Earnings power value estimate.

Comps Fair Value

$0.46

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 5 available valuation references for Mangoceuticals Inc (NASDAQ-MGRX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Mangoceuticals Inc (NASDAQ-MGRX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

315.227 K

Current operating scale indicator.

Revenue Forecast

456.021 K

Forward revenue estimate.

EBITDA

-12.097 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Mangoceuticals Inc (NASDAQ-MGRX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Mangoceuticals Inc (NASDAQ-MGRX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-201.7

Lower score that deserves closer risk review.

FCF / Net Income

23.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Mangoceuticals Inc (NASDAQ-MGRX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Mangoceuticals Inc (NASDAQ-MGRX)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

56

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Mangoceuticals Inc (NASDAQ-MGRX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Mangoceuticals Inc (NASDAQ-MGRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Mangoceuticals Inc (NASDAQ-MGRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Mangoceuticals Inc (NASDAQ-MGRX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Mangoceuticals Inc (NASDAQ-MGRX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Mangoceuticals Inc (NASDAQ-MGRX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ Fast Investor Answers

Mangoceuticals Inc (NASDAQ-MGRX) Stock FAQ

Data-supported answers about Mangoceuticals Inc (NASDAQ-MGRX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.44
Estimated downside 7.4%
Valuation Rating
Overvalued
Estimated downside of 7.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Mangoceuticals Inc (NASDAQ-MGRX) is $0.44. This implies an estimated downside of 7.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 7.4% versus the current market price.

The current financial health read for Mangoceuticals Inc (NASDAQ-MGRX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Mangoceuticals Inc (NASDAQ-MGRX) is November 13, 2026.

The latest available data indicates no current dividend yield for Mangoceuticals Inc (NASDAQ-MGRX).

The current market capitalization listed for Mangoceuticals Inc is 10.266 M.

The current enterprise value listed for Mangoceuticals Inc is 10.315 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Mangoceuticals Inc is NASDAQ-MGRX, and the stock is listed on NASDAQ.

Mangoceuticals Inc (NASDAQ-MGRX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Mangoceuticals Inc is 2.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Mangoceuticals Inc is 82.7%. Free float helps investors understand how much of the share base is available for public trading.